| Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. | |
| | |
MedLine Citation:
|
PMID: 14691611 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We have recently shown that accumulation in mouse kidneys of technetium-99m labeled phosphorodiamidate morpholinos (MORFs) increases with the number of cytosines in the base sequence. To improve tumor/kidney ratios in tumored mice, pretargeting studies were performed with a cytosine-free MORF. An 18-mer MORF (5'-TCTTCTACTTCACAACTA) was conjugated to the anti-CEA antibody MN14 (Immunomedics) and administered to nude mice bearing LS174T tumors. Thereafter, the (99m)Tc-labeled cytosine-free cMORF (5'-TAGTTGTGAAGTAGAAGA-amide-MAG(3)) was administered. For comparison, the identical study was repeated but with our original pair of 18-mer MORFs (5'-GGGTGTACGTCACAACTA-conjugated MN14 and (99m)Tc-labeled 5'-TAGTTGTGACGTACACCC-amide-MAG(3)). Surface plasmon resonance was used to show that the hybridization affinities of the original and the modified pair of MORFs were essentially equal. Hybridization of the cytosine-free cMORF-(99m)Tc to MN14-MORF was demonstrated in vitro by size-exclusion high-performance liquid chromatography. At 3 h, kidney levels in normal mice were 2.0%ID/organ for the modified cMORF vs. 4.1%ID/organ for the original cMORF sequence, while at 24 h, these values were 0.9% vs 1.8%ID/organ. Pretargeting studies in tumored mice receiving 25 microg of conjugated antibody, 0.5 microg of labeled cMORF 48 h later, followed by imaging and sacrifice at 3 h showed that kidney levels were reduced using the cytosine-free cMORF. Moreover, tumor accumulation was about 3.6%ID/g and was independent of sequence. The whole-body images clearly reflected the improved tumor to kidney ratios. By choosing a cytosine-free base sequence for pretargeting studies, kidney accumulation of cMORF-(99m)Tc was reduced without adversely influencing tumor accumulation. The lowering of kidney radioactivity levels in this way may be important to reduce toxicity to this organ in connection with pretargeting radiotherapy studies. |
| | |
Authors:
|
Guozheng Liu; Jiang He; Shuping Dou; Suresh Gupta; Jean-Luc Vanderheyden; Mary Rusckowski; Donald J Hnatowich |
Publication Detail:
|
Type: Comparative Study; Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S. Date: 2003-12-23 |
Journal Detail:
|
Title: European journal of nuclear medicine and molecular imaging Volume: 31 ISSN: 1619-7070 ISO Abbreviation: Eur. J. Nucl. Med. Mol. Imaging Publication Date: 2004 Mar |
Date Detail:
|
Created Date: 2004-03-01 Completed Date: 2004-11-24 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 101140988 Medline TA: Eur J Nucl Med Mol Imaging Country: Germany |
Other Details:
|
Languages: eng Pagination: 417-24 Citation Subset: IM |
Affiliation:
|
Department of Radiology, University of Massachusetts Medical School, Worcester, MA 01655-0243, Worcester, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cell Line, Tumor Colonic Neoplasms / metabolism*, radionuclide imaging* Humans Kidney / metabolism*, radionuclide imaging* Metabolic Clearance Rate Mice Mice, Nude Oligonucleotides / chemistry, diagnostic use*, pharmacokinetics* Organ Specificity Radiopharmaceuticals / chemistry, diagnostic use, pharmacokinetics Technetium / chemistry, diagnostic use, pharmacokinetics Tissue Distribution Tumor Markers, Biological / metabolism* |
| Grant Support | |
ID/Acronym/Agency:
|
CA79507/CA/NCI NIH HHS; CA94994/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Oligonucleotides; 0/Radiopharmaceuticals; 0/Tumor Markers, Biological; 7440-26-8/Technetium |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The prefrontal cortex: insights from functional neuroimaging using cognitive activation tasks.
Next Document: Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of...